PE52996A1 - FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO - Google Patents

FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO

Info

Publication number
PE52996A1
PE52996A1 PE1995286338A PE28633895A PE52996A1 PE 52996 A1 PE52996 A1 PE 52996A1 PE 1995286338 A PE1995286338 A PE 1995286338A PE 28633895 A PE28633895 A PE 28633895A PE 52996 A1 PE52996 A1 PE 52996A1
Authority
PE
Peru
Prior art keywords
fab
hla
mab
monoclonal antibody
presenting cells
Prior art date
Application number
PE1995286338A
Other languages
English (en)
Spanish (es)
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE52996A1 publication Critical patent/PE52996A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE1995286338A 1994-12-07 1995-12-04 FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO PE52996A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07

Publications (1)

Publication Number Publication Date
PE52996A1 true PE52996A1 (es) 1996-12-12

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995286338A PE52996A1 (es) 1994-12-07 1995-12-04 FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO

Country Status (19)

Country Link
EP (1) EP0787151A1 (cs)
JP (1) JP2001506122A (cs)
CN (1) CN1168679A (cs)
AR (1) AR002005A1 (cs)
AU (1) AU4256096A (cs)
BR (1) BR9509902A (cs)
CA (1) CA2206471A1 (cs)
CO (1) CO4480041A1 (cs)
CZ (1) CZ172497A3 (cs)
FI (1) FI972430L (cs)
HU (1) HUT77342A (cs)
IL (1) IL116228A0 (cs)
MA (1) MA23739A1 (cs)
NO (1) NO972522L (cs)
PE (1) PE52996A1 (cs)
PL (1) PL320610A1 (cs)
TR (1) TR199501542A2 (cs)
WO (1) WO1996017874A1 (cs)
ZA (1) ZA9510195B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
AU5588099A (en) * 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
EP1156060B1 (en) * 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
US6894149B2 (en) 2001-10-11 2005-05-17 Protein Design Labs, Inc. Anti-HLA-DA antibodies and the methods of using thereof
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
CA2794499A1 (en) * 2010-04-01 2011-10-06 Immumomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
DE69028713T3 (de) * 1989-12-27 2004-05-13 Centocor, Inc. Schimäre immunoglobuline für cd4-rezeptoren
ES2196002T3 (es) * 1991-07-25 2003-12-16 Idec Pharma Corp Anticuerpos recombinantes para terapia humana.

Also Published As

Publication number Publication date
BR9509902A (pt) 1997-10-21
AR002005A1 (es) 1998-01-07
AU4256096A (en) 1996-06-26
JP2001506122A (ja) 2001-05-15
CA2206471A1 (en) 1996-06-13
TR199501542A2 (tr) 1996-07-21
PL320610A1 (en) 1997-10-13
EP0787151A1 (en) 1997-08-06
CN1168679A (zh) 1997-12-24
NO972522L (no) 1997-08-06
IL116228A0 (en) 1996-03-31
FI972430A7 (fi) 1997-06-06
FI972430A0 (fi) 1997-06-06
NO972522D0 (no) 1997-06-03
ZA9510195B (en) 1996-06-07
WO1996017874A1 (en) 1996-06-13
CZ172497A3 (en) 1997-10-15
MX9704225A (es) 1997-09-30
HUT77342A (hu) 1998-03-30
FI972430L (fi) 1997-06-06
MA23739A1 (fr) 1996-07-01
CO4480041A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
USRE49435E1 (en) Glycan-interacting compounds and methods of use
Wolbink et al. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
US8119135B2 (en) Antibodies which bind to epitopes of glycoprotein VI
Capra et al. Light chain sequences of human IgM cold agglutinins
US12552873B2 (en) Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
US20160130356A1 (en) Glycan-interacting compounds and methods of use
AR021296A1 (es) Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden
EP1461073A4 (en) PEPTIDAGONISTS FOR PROSTATE-SPECIFIC ANTIGEN AND THEIR USE
US20220396627A1 (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
PE20061323A1 (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
PE52996A1 (es) FRAGMENTO mAb MONOVALENTE (fab) DE mAb QUE TIENE LA CAPACIDAD DE REDUCIR LA SENSIBILIDAD DE LA EXPRESION DEL HLA-DR EN CELULAS PRESENTADORAS DEL ANTIGENO
Hansen et al. A mouse aminopeptidase N is a marker for antigen‐presenting cells and appears to be co‐expressed with major histocompatibility complex class II molecules
Lesley et al. Effect of antigen density on complement-mediated lysis, T-cell-mediated killing, and antigenic modulation
Baniel et al. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
ES2338919T3 (es) Anticuerpos anti-receptor ccr7 para el tratamiento del cancer.
EP3990015A1 (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
Sundsmo et al. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
EP1476467B9 (fr) Immunoglobuline igg3 marqueur de protection contre les maladies virales infectieuses et ses utilisations
Gammelgaard et al. Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activity
Roos et al. Both IgG and IgM anti‐pig antibodies induce complement activation and cytotoxicity
KR20220042131A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-lrrc25 조성물 및 방법, 그리고 이의 용도
Yano et al. Natural antibodies against the immunoglobulin F (ab′) 2 fragment cause elimination of antigens recognized by the F (ab′) 2 from the circulation
Lehuen et al. Identification of a surface protein (p100) associated with two glycosyl‐phosphatidylinositol‐linked molecules (Thy‐1 and ThB) by natural anti‐lymphocyte autoantibodies

Legal Events

Date Code Title Description
FD Application declared void or lapsed